New Retina Radio By Eyetube

No two secondary IOL procedures are the same, and each case requires your full attention. What is your favorite technique? How are you protecting the haptics and avoiding hypotony? Hear from four of the top retina surgeons on their preferred approaches and how they avoid common surgical pitfalls. A conversation with Christina Y. Weng, MD, MBA; Ashkan M. Abbey, MD; María H. Berrocal, MD; and Omesh P. Gupta, MD, MBA

Punctate inner choroidopathy-like, or PIC-like, reactions are rare, and they sometimesl confound retina specialists. New Retina Radio Journal Club with VBS panelists Kyle Kovacs, MD, and Priya Vakharia, MD, join moderator Yasha Modi, MD, to review a retrospective observational study of patients with PIC-like presentations in unrelated chorioretinal disorders.

Two biosimilars have been approved by the US FDA, and more are going to receive approval soon. With this level of disruption in US retina practice, what do you need know? George Williams, MD, the Senior Secretary for Advocacy at the AAO, joined us for preview on what practice might look like now that biosimilars are a fact of life. Also, Caroline Baumal, MD, sat down with us to discuss the YOSEMITE and RHINE studies, which released 2-year results. How did patients receiving faricimab (Vabysmo, Genentech/Roche) respond during their second year of treatment? 

John Kitchens, MD, invites Aleksandra Rachitskaya, MD, and Jonathan Russell, MD, PhD, to discuss the use of imaging technology in the retina clinic. The surgeons discuss cases in which they share approaches to imaging to evaluate wet age-related macular degeneration, retinal detachments, and more. They explain the value of OCT, ultra-widefield imaging, and fluorescein angiography, and comment on the use of change analysis with the Cirrus 6000 and Retina Workplace. Finally, the trio provides insights into the potential future of imaging technology. This podcast is sponsored by ZEISS.

We know about long-term intravitreal injections that might slow the progression of geographic atrophy (GA). But could a gene therapy in the pipeline require fewer treatments and still yield results? Jeffrey Heier, MD, summarized an AAO presentation on the phase 1 data of JNJ-1887 (Janssen), a potential gene therapy for GA. Was it safe—and were there signs of efficacy? Michel Michaelides, BSc, MB,, BS MD(Res), FRCOphth, joined us to speak about a gene therapy targeting x-linked retinitis pigmentosa. With a phase 3 study for the drug AAV5-RPGR (Jannsen/MeiraGTx) already underway, what can we learn from earlier trial results? 

Two biosimilars have been approved for retinal indications. What conclusions were drawn from the phase 3 studies that preceded their approval? Yasha Modi, MD, is joined by Kyle Kovacs, MD, and Priya Vakharia, MD, to review the ins and outs of biosimilarity, discuss the findings of two recent papers, and consider how use of biosimilars might affect future clinical practice in the United States. 

Identifying systemic biomarkers indicating risk for age-related macular degeneration would be a game-changer. But how can we find those biomarkers? We spoke with Joan Miller, MD, whose work with the Harvard Retina Metabolomics Program focuses on identifying specific metabolites that might be useful in real-world practice. Also, Yannek Leiderman, MD, PhD, stopped by to fill us in on the state of artificial intelligence (AI) in the OR. How far away are surgeons from interacting in real time with AI? 

Phase 3 data evaluating the biosimilarity of a new biosimilar (Xlucane, Xbrane Biopharma) referencing ranibizumab (Lucentis, Genentech) has been completed. What were the results? Anat Loewenstein, MD, joined New Retina Radio to walk us through the results of the XPLORE study. And Ramanath Bhandari, MD, summarized his presentation on the TRUCKEE study, a real-world evaluation of the performance of faricimab (Vabysmo, Genentech/Roche). What do the most recent updates tell us about practice patterns and patient response?

Researchers in the second pivotal study evaluating the safety and efficacy of avacincaptad pegol (Zimura, IVERIC bio) for the treatment of geographic atrophy have released 1-year results. New Retina Radio spoke with Arshad Khanani, MD, MS, about the GATHER2 study findings. How did the study results compare to the GATHER1 conclusions—and might the company move forward with a regulatory filing?

What is the effect of laser prophylaxis in patients with Stickler Syndrome, and just how effective are buckles in patients with GRT detachments? Yoshi Yonekawa, MD, PhD, is joined by Peter Campbell, MD; Karen Jeng-Miller, MD; and Prethy Rao, MD, to review two recent contributions to the literature, during which they probe the papers' findings and explore their limitations.

What changed in the most recent iteration of the International Classification of Retinopathy of Prematurity? And what do new data tell us about how ROP patients fare in adulthood? To find out, Yoshi Yonekawa, MD, PhD, is joined by Peter Campbell, MD; Karen Jeng-Miller, MD; and Prethy Rao, MD, to break down the latest literature, examine the papers' limitations, and offer pearls for surgical management of adults with history of ROP. 

Can a quantitative analysis of OCT images detect early diabetic retinopathy in patients without symptoms? New Retina Radio spoke with Jennifer Lim, MD, whose research team sought to learn whether imaging analyses of photoreceptor length and reflectivity parameters could serve as a biomarker for disease detection.  We also sat down with Lejla Vajzovic, MD, who shared data on a pair of phase 1 studies assessing the safety and efficacy of two gene therapies for achromatopsia. One of those two drugs will be going on for further study. Which one? Stick with us to find out. 

Retina specialists may wish to turn to the literature to learn more about multifocal, indolent, nonprogressive choroidal lesions. Let the New Retina Radio Journal Club with VBS help you out. Moderator Kyle Kovacs, MD, is joined by Cynthia Qian, MD, and David Xu, MD, to review two recent papers on this atypical presentation. 

Was treat-and-extend faricimab (Vabysmo, Genentech) an effective means of controlling DME in the YOSEMITE and RHINE studies? New Retina Radio spoke with John Kitchens, MD, whose ASRS presentation reviewed results from a pair of phase 3 studies that assessed, in part, 12- and 16-week dosing intervals of faricimab in patients with DME.  Also joining us is Michael Allingham, MD, PhD. He shared results from the phase 2b ZETA-1 study, which examined the safety and efficacy of APX3330 (Ocuphire Pharma), an oral medication for DR. What promise might this treatment hold? Tune in to learn more.  This editorially independent podcast is supported with advertising.

Treat-and-extend regimens has been used for thousands of wet AMD patients. How does brolucizumab (Beovu, Novartis) stack up when compared with aflibercept (Eylea, Regeneron) in a matched treat-and-extend study? New Retina Radio spoke with Carl Regillo, MD, a member of the TALON study group, which sought to find out if brolucizumab was superior to aflibercept for extending treatment intervals in wet AMD patients.    We also spoke with Carl Danzig, MD, whose work on the TRUCKEE study illuminates real-world treatment dynamics when it comes to the use of faricimab (Vabysmo, Genentech) in wet AMD treatment. How are patients responding in the real world? 

How might two recent contributions to the literature deepen our understanding of recurrent rhegmatogenous retinal detachment (RRD)? To find out, moderator Kyle Kovacs, MD, is joined by panelists Cynthia Qian, MD, and David Xu, MD, to review a pair of papers on the topic. After the break, the group tackles tamponade selection and use of scleral buckles in patients with RRD, and discusses tactics for bringing a patient back to the OR if RRD recurs. This editorially independent podcast is supported with advertising.

In this episode, John W. Kitchens, MD, speaks with Steve Charles, MD, FACS, FICS, FASRS, a vitreoretinal surgeon and founder of the Charles Retina Institute in Germantown, Tennessee, as well as clinical professor of ophthalmology at the University of Tennessee in Memphis. Known to many as the architect behind the ACCURUS and CONSTELLATION from Alcon, his career is wildly impressive, but Dr. Kitchens finds his life and career history even more fascinating. This podcast is editorially independent.

What are the latest findings regarding pentosan poloysulfate maculopathy (PPM)? Moderator Basil Williams, MD, invites panelists Karen Jeng-Miller, MD, MPH; M. Ali Khan, MD; and Katherine Talcott, MD, to review two recent publications seeking to better characterize the condition After the break, the discussion turns to the utility of imaging modalities in PPM management and an exploration into hospital-based policies that might lead to earlier detection of PPM in patients undergoing a new course of pentosan polysulfate sodium therapy. 

Could an 8-mg dose intensify the therapeutic effect of aflibercept (Eylea, Regeneron) in patients with wet AMD? The phase 2 CANDELA study sought to explore the safety and efficacy of high-dose aflibercept in this patient population. What did Dave Brown, MD, and his research colleagues observe?  And 96-week data from ARCHWAY are in. Did the complete study, which reached its primary endpoint after 40 weeks, reveal new data that could affect clinical decision-making when it comes to real-world use of the Port Delivery System with Ranibizumab (Susvimo, Genentech)? Hear our interview with Robert Mittra, MD, to find out.  This editorially independent podcast is supported with advertising.

Could RPE cell replacement therapy be the future of GA treatments? Retina Today’s Chief Medical Editor Allen C. Ho, MD, joined us to discuss observations from a phase 1/2a study evaluating the safety and efficacy of OpRegen (Lineage Cell Therapeutics), a suspension of allogenic RPE cells implanted in the subretinal space. How well was this therapy tolerated, and were there any signs of vision improvement?   Elsewhere in the GA pipeline, researchers are exploring whether the gene therapy GT005 (Gyroscope Therapeutics) might be a safe and effective one-time treatment for GA via upregulation of complement factor I. How does complement factor I affect the course of GA, and what are the latest data from a phase 1/2 study? Check out this episode to hear on conversation on that topic with Jared Nielsen, MD, MBA.   This podcast is editorially independent, supported with advertising.